Blas Coll Crespo, Chief Medical Officer of Structure Therapeutics Inc. (NASDAQ:GPCR), filed a Form 4 on September 22, 2026, disclosing share withholding, conversion, and sale transactions in ordinary shares and American Depositary Shares dated September 18 and September 21, 2026.

Key Highlights

  • Tax withholding: 10,626 ordinary shares were withheld by the issuer on September 18, 2026, at $11.67 per share to satisfy income tax obligations associated with the vesting of a restricted share unit award.
  • Conversion: On September 21, 2026, 12,024 ordinary shares were converted into 4,008 American Depositary Shares (ADSs), with each ADS representing three ordinary shares.
  • ADS sale: 4,008 ADSs were sold on September 21, 2026, at $36.1459 per ADS pursuant to a Rule 10b5-1 trading plan entered into on March 30, 2026.
  • Remaining ordinary shares: Following all transactions, Coll Crespo directly holds 258,228 ordinary shares.
  • Remaining ADSs: Following the reported transactions, Coll Crespo directly holds 1,157 ADSs.
  • 10b5-1 plan: The ADS sale was made pursuant to a pre-established Rule 10b5-1 trading plan, as indicated on the filing's cover checkbox.

Details of the CMO's Reported Transactions in Structure Therapeutics Securities

According to the filing, the first transaction on September 18, 2026, involved the disposition of 10,626 ordinary shares withheld by the issuer at a price of $11.67 per share (reported as price per ordinary share) to cover income tax obligations related to the vesting of a restricted share unit award. Following that transaction, Coll Crespo directly held 270,252 ordinary shares, the filing states.

On September 21, 2026, the filing discloses that 12,024 ordinary shares were converted into 4,008 ADSs at a conversion price of $0, reducing the direct ordinary share count to 258,228. The filing notes that each ADS is convertible at the holder's election into three ordinary shares and carries no expiration date. In the same session, the filing reports that the 4,008 ADSs were then sold at $36.1459 per ADS under a Rule 10b5-1 trading plan that the reporting person had entered into on March 30, 2026, leaving a remaining direct ADS position of 1,157 units.

The Form 4 was signed by Jun Yoon as Attorney-in-Fact and filed on September 22, 2026. The filing identifies Coll Crespo as an officer of Structure Therapeutics Inc. in the role of Chief Medical Officer, with all reported holdings held directly.

What Was Disclosed

The filing disclosed three transactions by Structure Therapeutics' Chief Medical Officer: a tax-related share withholding on September 18, 2026, and a share conversion followed by an ADS sale on September 21, 2026, the latter executed under a pre-established Rule 10b5-1 plan.